In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.
Two years after it was announced that the ARV dolutegravir would become part of standard first line HIV treatment in South Africa, it is finally reaching significant numbers of people. But new research about a worrying side-effect, weight gain (particularly in women), has muddied its otherwise stellar reputation.
People in South Africa who have recovered from COVID-19 are donating their blood to help others who are trying to fight off the disease that has so far claimed over 200 lives and infected over 10 000 people in the country.
Many journalists, including us, are finding the quantity of science reports on COVID-19 overwhelming. We introduce a new occasional column to help make sense of the information overload. The aim of this occasional column, which we’re calling COVID-19 Report, will be to alert reporters in South Africa (and anyone else who is interested) to the best and most important science, and also clear up misconceptions.
Scientific research on COVID-19 has been published at an unprecedented scale and speed, but some fear that this is at the cost of scientific rigour. Adele Baleta explores the pros and cons of high-speed science.